Glipizide - immediate-release tablets | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Review first - source-specific qualification

Before use: Glipizide - immediate-release tablets

The IR label gives conservative initiation and maintenance advice; the newly retrieved ER label explicitly starts hypoglycemia-prone patients, including renal impairment, at 2.5 mg.

Before applying: Select immediate-release versus extended-release before applying the starting instruction; do not invent a CrCl-based schedule.

Evidence for this qualification

Source-specific interpretation; independent clinician adjudication pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Glipizide - immediate-release tablets

Product / population: Adults with type 2 diabetes; Advagen immediate-release glipizide tablets.
Renal measure: Qualitative renal impairment; no numbered CrCl bands.

Renal guidance and important limits

Limits that apply to these rows

Reduced metabolism/excretion may prolong hypoglycemia. Monitor glucose closely, especially with poor intake, other glucose-lowering drugs or intercurrent illness.

The 2.5 mg example for geriatric/liver disease in the dosage section is not an explicit universal renal starting dose. Do not import the ER instruction as an IR renal rule.

Glipizide IR - renal caution
Population	Source-specific instruction
Impaired renal function	Use conservative initial AND maintenance dosing to avoid hypoglycemia. No numerical renal table supplied.

Read the retained text before reformatting

Glipizide IR - renal caution

Population	Source-specific instruction
Impaired renal function	Use conservative initial AND maintenance dosing to avoid hypoglycemia. No numerical renal table supplied.

Reduced metabolism/excretion may prolong hypoglycemia. Monitor glucose closely, especially with poor intake, other glucose-lowering drugs or intercurrent illness.

The 2.5 mg example for geriatric/liver disease in the dosage section is not an explicit universal renal starting dose. Do not import the ER instruction as an IR renal rule.

Source revision: Revision not established in selected retrieval | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e954afb8-52eb-416a-8f1b-14b0fcb3bac2

Scope: Selected source sections stored locally. Not a complete monograph or independent clinical approval. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Glipizide - immediate-release tablets

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Before using this finding

Select immediate-release versus extended-release before applying the starting instruction; do not invent a CrCl-based schedule.

Adults with type 2 diabetes; Advagen immediate-release glipizide tablets.

Renal method: Qualitative renal impairment; no numbered CrCl bands.
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Before use: Glipizide - immediate-release tablets

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source scope and renal guidance

Before use: Glipizide - immediate-release tablets

The IR label gives conservative initiation and maintenance advice; the newly retrieved ER label explicitly starts hypoglycemia-prone patients, including renal impairment, at 2.5 mg.

How to use this: Select immediate-release versus extended-release before applying the starting instruction; do not invent a CrCl-based schedule.

Glipizide - immediate-release tablets

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Official source

Glipizide - immediate-release tablets

Adults with type 2 diabetes; Advagen immediate-release glipizide tablets.

Method: Qualitative renal impairment; no numbered CrCl bands.

Renal guidance and important limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope Glipizide - immediate-release tablets

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e954afb8-52eb-416a-8f1b-14b0fcb3bac2

Exact product and population

Adults with type 2 diabetes; Advagen immediate-release glipizide tablets.

RDM64-SCOPE-glipizide-immediate-release · Source section: Selected source product scopeRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

Glipizide - immediate-release tablets

Open original reference

Open / share this exact local source

DailyMed / NLM exact product labeling · Adults with type 2 diabetes; Advagen immediate-release glipizide tablets.

Renal method: Qualitative renal impairment; no numbered CrCl bands.
Source date: Revision not established in selected retrieval
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Before using this finding

Select immediate-release versus extended-release before applying the starting instruction; do not invent a CrCl-based schedule.

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

Reduced metabolism/excretion may prolong hypoglycemia. Monitor glucose closely, especially with poor intake, other glucose-lowering drugs or intercurrent illness.

The 2.5 mg example for geriatric/liver disease in the dosage section is not an explicit universal renal starting dose. Do not import the ER instruction as an IR renal rule.

Glipizide IR - renal caution
Population	Source-specific instruction
Impaired renal function	Use conservative initial AND maintenance dosing to avoid hypoglycemia. No numerical renal table supplied.

Read the retained text before reformatting

Glipizide IR - renal caution

Population	Source-specific instruction
Impaired renal function	Use conservative initial AND maintenance dosing to avoid hypoglycemia. No numerical renal table supplied.

Reduced metabolism/excretion may prolong hypoglycemia. Monitor glucose closely, especially with poor intake, other glucose-lowering drugs or intercurrent illness.

The 2.5 mg example for geriatric/liver disease in the dosage section is not an explicit universal renal starting dose. Do not import the ER instruction as an IR renal rule.

RDM64-official-glipizide-immediate-release-fe21d4d077-C1 · Source locator: Precautions: renal/hepatic disease and hypoglycemia; Dosage and Administration.

Source-specific limits

Reduced metabolism/excretion may prolong hypoglycemia. Monitor glucose closely, especially with poor intake, other glucose-lowering drugs or intercurrent illness.

The 2.5 mg example for geriatric/liver disease in the dosage section is not an explicit universal renal starting dose. Do not import the ER instruction as an IR renal rule.

Source identity and provenance

Source family: product_label
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e954afb8-52eb-416a-8f1b-14b0fcb3bac2
Retrieved: 2026-09-10
Exact label title: Glipizide - immediate-release tablets
DailyMed Set ID: e954afb8-52eb-416a-8f1b-14b0fcb3bac2
Label revision: Revision not established in selected retrieval
Renal-function method: Qualitative renal impairment; no numbered CrCl bands.
Source date/version: Revision not established in selected retrieval
Hash meaning: Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256: a3fa030075af21e7d69469a990f8a3aef9314a2f6306ecd38a50499023aa5b1a

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e954afb8-52eb-416a-8f1b-14b0fcb3bac2
Source retrieval: 2026-09-10. This is not the source publication or label revision date.
Original source type: rxlist summary
Local text SHA-256: 3771ea65d22f6fe54833cc86f92a4bb8137d4ecd9c03f8728fb8a8b17dd3861c
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report